Phase 3 Win: Takeda's CLDN18.2 ADC Cuts Death Risk 43% in Advanced Gastric Cancer
TAK sits 57% above its 52-week low of $12.99.
Summary
Takeda's arcotatug tavatecan (TAK-921), a CLDN18.2-targeted antibody-drug conjugate licensed from Innovent, hit both primary endpoints in the Phase 3 G-HOPE-001 study in previously treated, CLDN18.2-positive advanced gastric/GEJ adenocarcinoma. Median overall survival was 10.2 months versus 6.9 months for physician's-choice chemotherapy (HR=0.57, P<0.0001), and median PFS was 7.1 versus 3.1 months (HR=0.45). Confirmed ORR was 37.4% versus 7.7%, with a manageable safety profile and a Grade ≥3 TRAE rate of 47.4% versus 55.9%. The data support a planned regulatory filing in Japan, while Innovent's China NDA has been accepted under Priority Review; Takeda also plans global Phase 3 trials in gastric and pancreatic cancer. This is a genuine pipeline win for an oncology franchise that has already delivered ORZEYFUL and MIMRYLO approvals this year, and it comes with the stock trading near its 52-week high. Watch for the Japan filing submission and the timing of the global Phase 3 starts.
At the time of this announcement, TAK was trading at $20.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $64.6B. The 52-week trading range was $12.99 to $20.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.